AustraliaHealth

The US FDA has accepted Telix Pharmaceuticals' (ASX:TLX) NDA for brain cancer imaging agent Pixclara.

AVITA Medical (ASX:AVH) has finalised a ten-year agreement with the Biomedical Advanced Research and Development Authority valued at up to $25.5 million.

FDA clears Mesoblast (ASX:MSB) will begin a registrational trial for Ryoncil in treating Duchenne muscular dystrophy.

Imricor Medical Systems (ASX:IMR) submitted its NorthStar 3D Mapping System for FDA clearance.

Lumos Diagnostics (ASX:LDX) announced a new three-year contract manufacturing agreement for the innovative Micro-Pak Mold Analyser system.

Radiopharm Theranostics (ASX:RAD) reached a clinical milestone following a positive recommendation from the Data Safety and Monitoring Committee.

Pro Medicus (ASX:PME) secured a five-year, $23 million contract with the University of Maryland Medical System.

Telix Pharmaceuticals (ASX:TLX) logged an 11% quarter-over-quarter increase in group revenue to US$230 million for the period ended March 31.

Medical technology firm ImpediMed (ASX:IPD) appointed Erik Anderson as Managing Director and CEO, effective April 7.

Mesoblast (ASX:MSB) announced that net sales for its flagship product, Ryoncil, reached US$30.3 million for the quarter ended March 31.

Amplia Therapeutics (ASX:ATX) announced a shift in its clinical programme, halting further recruitment for the AMPLICITY trial.

AFT Pharmaceuticals (ASX:AFP) recorded sustained double-digit sales growth across its entire global portfolio for the March quarter of 2026.